Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 13, Issue 2, pp. 433-443
PubMed
Published By
Print ISSN
Online ISSN
History
- Received September 24, 2013
- Revision received December 2, 2013
- Accepted December 8, 2013
- Published first December 19, 2013.
Article Versions
- Previous version (December 19, 2013 - 12:48).
- Previous version (January 28, 2014 - 14:55).
- You are viewing the most recent version of this article.
Copyright & Usage
©2013 American Association for Cancer Research.
Author Information
- Junko Murai1,4,
- Shar-Yin N. Huang1,
- Amèlie Renaud1,
- Yiping Zhang2,
- Jiuping Ji2,
- Shunichi Takeda4,
- Joel Morris3,
- Beverly Teicher3,
- James H. Doroshow1,3, and
- Yves Pommier1,3
- Authors' Affiliations: 1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
- Corresponding Author:
Yves Pommier, Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Building 37, Room 5068, NIH, Bethesda, MD 20892-4255. Phone: 301-496-5944; Fax: 301-402-0752; E-mail: pommier{at}nih.gov
February 2014
Volume 13, Issue 2
Volume 13, Issue 2
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Jump to section
Advertisement